Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01233778 · ClinicalTrials.gov registry record · NA
Canola Oil Multicentre Intervention Trial (COMIT)
A NA study of Cardiovascular Disease, sponsored by Penn State University.
- Completed
- Registry status
- NA
- Development phase
- 43
- Enrollment target
- 1
- Study location
NCT01233778: Completed NA study of Cardiovascular Disease, sponsored by Penn State University.
NCT01233778 is a NA study of Cardiovascular Disease that has completed, run by Penn State University. The registered enrollment target is 43 participants, below the 2,697-participant average among 137 other Cardiovascular Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01233778, a NA study of Cardiovascular Disease, has completed, sponsored by Penn State University.
- COMPLETED
- Registry status
- NA
- Development phase
- 43 participants
- Enrollment target
- 1
- Study location
Study Summary
The objectives of this study are to examine how the consumption of treatment oils (including canola oil, DHA enriched canola-oil, high oleic acid canola oil, flax oil, and safflower oil) influence endothelial function, inflammation, oxidation, body composition, and plasma lipoprotein characterization.
Primary Outcome
Study subjects will undergo endothelial health assessment by EndoPAT analysis. The EndoPat procedure will occur while the subject is lying down in a relaxed state. Throughout the study, the inflation pressure of the EndoPAT device will be electronically set to 10mm Hg below diastolic BP. Testing begins with 10 min of rest. Following rest, baseline pulse amplitude is measured from each fingertip for 5 min. Next, arterial flow is interrupted for 5 min by a cuff placed on the forearm at an occlusio
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Safflower Oil
- DIETARY_SUPPLEMENT Canola Oil
- DIETARY_SUPPLEMENT High Oleic Acid + DHA Canola Oil
- DIETARY_SUPPLEMENT High Oleic Acid Canola Oil
- DIETARY_SUPPLEMENT Flax Oil
Study Locations (1)
Pennsylvania
- Penn State University - University Park
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2010-10 |
| Est. Completion | 2012-04 |
| Phase | NA |
What the finished NCT01233778 record still lists
NCT01233778 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 2,697-participant average among 137 other Cardiovascular Disease trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Cardiovascular Disease appearing as the primary indexed condition, and to 5 interventions - of which Safflower Oil is the first listed.
NCT01233778 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01233778 about?
NCT01233778 is a clinical study titled "Canola Oil Multicentre Intervention Trial (COMIT)". The objectives of this study are to examine how the consumption of treatment oils (including canola oil, DHA enriched canola-oil, high oleic acid canola oil, flax oil, and safflower oil) influence endothelial function, inflammation, oxidation, body composition, and plasma lipoprotein characterizatio...
What is the current status of trial NCT01233778?
This trial is currently completed. It is a NA study. The enrollment target is 43 participants. The study started on 2010-10. Estimated completion is 2012-04.
What conditions does trial NCT01233778 study?
This clinical trial studies the following conditions: Cardiovascular Disease.
What interventions are being tested in trial NCT01233778?
The interventions under investigation include: Safflower Oil (DIETARY_SUPPLEMENT), Canola Oil (DIETARY_SUPPLEMENT), High Oleic Acid + DHA Canola Oil (DIETARY_SUPPLEMENT), High Oleic Acid Canola Oil (DIETARY_SUPPLEMENT), Flax Oil (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01233778?
This trial is sponsored by Penn State University, which has 219 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01233778 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cardiovascular Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01233778's enrollment target sits among peer trials
43 113th of 137 higher than 23 of 137 other Cardiovascular Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cardiovascular Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients
RECRUITING · NA
-
A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors
RECRUITING · NA
-
Gauging Outcomes of Total Milk Ingestion on Lipid and gControl
RECRUITING · NA
-
Determining the Benefits of Exercise on Cardiovascular Risk in PTSD
RECRUITING · NA
-
Century Trial, a Randomized Lifestyle Modification Study for Management of Stable Coronary Artery Disease
ACTIVE NOT RECRUITING · NA
-
Nitric Oxide Bioavailability and Early Life Stress (NO-Stress)
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia